Alison M. Graham

A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors

James M. Cleary, Caio Max S. Rocha Lima, Herbert I. Hurwitz et al. · Investigational New Drugs · 2014 · 79 citations

Medicine, Oncology, Pharmacology +12

Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy

Richard Gray, Smitaa Patel, Natalie Ives et al. · JAMA Neurology · 2021 · 60 citations · Full text

Medicine, Neurology, Pharmacology +14

The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study

Matthew S. Davids, Andrew W. Roberts, Mary Ann Anderson et al. · Blood · 2012 · 40 citations

Medicine, Oncology, Pharmacology +16

Investigation of the interaction between argatroban and acetaminophen, lidocaine, or digoxin

Anne Marie L. Inglis, Sunita B. Sheth, Marcie J. Hursting et al. · American Journal of Health-System Pharmacy · 2002 · 36 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

John F. Seymour, Matthew S. Davids, John M. Pagel et al. · Journal of Clinical Oncology · 2013 · 33 citations

Medicine, Oncology, Pharmacology +13